Your browser doesn't support javascript.
loading
Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis.
Biswas, Mohitosh; Rahaman, Shawonur; Biswas, Tapash Kumar; Haque, Zahirul; Ibrahim, Baharudin.
Afiliação
  • Biswas M; Department of Pharmacy, University of Rajshahi, Rajshahi, Bangladesh, biswas_07pharm@ru.ac.bd.
  • Rahaman S; Department of Pharmacy, University of Rajshahi, Rajshahi, Bangladesh.
  • Biswas TK; Department of Medicine, Faridpur Medical College Hospital, Faridpur, Bangladesh.
  • Haque Z; Department of Medicine, Rajshahi Medical College Hospital, Rajshahi, Bangladesh.
  • Ibrahim B; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Intervirology ; : 1-12, 2020 Dec 09.
Article em En | MEDLINE | ID: mdl-33296901
ABSTRACT

INTRODUCTION:

Although severe acute respiratory syndrome coronavirus-2 infection is causing mortality in considerable proportion of coronavirus disease-2019 (COVID-19) patients, however, evidence for the association of sex, age, and comorbidities on the risk of mortality is not well-aggregated yet. It was aimed to assess the association of sex, age, and comorbidities with mortality in COVID-2019 patients.

METHODS:

Literatures were searched using different keywords in various databases. Relative risks (RRs) were calculated by RevMan software where statistical significance was set as p < 0.05.

RESULTS:

COVID-19 male patients were associated with significantly increased risk of mortality compared to females (RR 1.86 95% confidence interval [CI] 1.67-2.07; p < 0.00001). Patients with age ≥50 years were associated with 15.4-folds significantly increased risk of mortality compared to patients with age <50 years (RR 15.44 95% CI 13.02-18.31; p < 0.00001). Comorbidities were also associated with significantly increased risk of mortality; kidney disease (RR 4.90 95% CI 3.04-7.88; p < 0.00001), cereborovascular disease (RR 4.78; 95% CI 3.39-6.76; p < 0.00001), cardiovascular disease (RR 3.05 95% CI 2.20-4.25; p < 0.00001), respiratory disease (RR 2.74 95% CI 2.04-3.67; p < 0.00001), diabetes (RR 1.97 95% CI 1.48-2.64; p < 0.00001), hypertension (RR 1.95 95% CI 1.58-2.40; p < 0.00001), and cancer (RR 1.89; 95% CI 1.25-2.84; p = 0.002) but not liver disease (RR 1.64 95% CI 0.82-3.28; p= 0.16).

CONCLUSION:

Implementation of adequate protection and interventions for COVID-19 patients in general and in particular male patients with age ≥50 years having comorbidities may significantly reduce risk of mortality associated with COVID-19.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Risk_factors_studies / Systematic_reviews Idioma: En Revista: Intervirology Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Risk_factors_studies / Systematic_reviews Idioma: En Revista: Intervirology Ano de publicação: 2020 Tipo de documento: Article